CSL 2025 Annual Report

Biodegradability of CSL’s products CSL’s commitment to a healthier world is embedded in its operational practices and policies, aimed at minimising environmental impact and reducing the risk of environmental harm. In line with this commitment, CSL Vifor conducted a study in FY2025 to assess the biodegradability of five of its products under aerobic aquatic conditions. This assessment covered only the products and did not consider their packaging. The study was carried out in collaboration with LAUS GmbH, a certified laboratory in Germany, following internationally recognised guidelines – OECD 301B and EU Method C.4-C.1 Each product sample was combined with activated sludge from a municipal wastewater treatment plant2 and monitored over a 28-day period to measure carbon dioxide (CO₂) evolution, an indicator of biodegradation3. The results showed that four out of five CSL Vifor products tested are readily biodegradable. Given that many CSL Behring products are derived from human plasma, a naturally occurring biological material, the risk of environmental persistence is inherently low. Nonetheless, CSL remains committed to a healthier environment and will continue to evaluate the biodegradability of additional products in its portfolio in the near future. 1. Test Guideline describing the CO2 Evolution test method that permits the screening of chemicals for biodegradability. 2. The plant primarily processes domestic water. 3. The pass level for ready biodegradability is 60% within the 10-day window for pure substances respectively 60% after 28 days for mixtures based on ThCO2 production. As the test item is a mixture, the 10-day-window criterion does not apply. Meeting the global demand for iron-based therapies A new CSL Vifor manufacturing facility in St. Gallen, Switzerland, has a modular design that can be expanded – cube by cube – to meet future needs. CSL Vifor a leader in iron-based therapies, recently opened Multicube, a state-of-the-art manufacturing facility that will help meet the increasing global demand for iron-based therapies needed to treat iron deficiency and iron deficiency anaemia. The new facility in St. Gallen, Switzerland increases CSL Vifor’s ability to produce the active pharmaceutical ingredient (API) in its iron products – and the building has an innovative design. The facility can be expanded by adding additional ‘cubes’ when future capacity is needed. Multicube was also designed with sustainability in mind. “The Multicube project is not only increasing the current active pharmaceutical ingredient (API) production capacity for our iron products but also has a sustainability focus. With the newest technologies, we will be able to recover the heat created during our production with condensate collectors and reuse it to heat the whole manufacturing site, providing possible energy savings and emissions benefits.” Abdullah Karakoc, Team Leader Project Engineering. Additionally, a photovoltaic system will enable the site to produce some of the electricity it needs, thereby reducing reliance on purchased electricity. 39 CSL Limited Annual Report 2024/25 + READ MORE AT CSL.COM/SUSTAINABILITY/HEALTHIER ENVIRONMENT/CLIMATE RESILIENCE

RkJQdWJsaXNoZXIy MjE2NDg3